A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was whether a mechanical or bioprosthetic valve is superior for immediate and long-term survival in patients with end-stage renal disease (ESRD) undergoing a valve replacement. Altogether more than 150 papers were found using the reported search; of which, eight represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. There were no randomized controlled trials addressing the question. There was one systematic review and meta-analysis. All the other evidence was in the form of retrospective studies. The papers show that there is no significant difference in the results and survival between patients receiving a mechanical and those receiving a bioprosthetic valve. This was seen in the meta-analysis as well as the larger series of patients who underwent valve replacement. Bleeding complications were more common with mechanical valves. We conclude that the choice of valve for patients with ESRD should be determined by age, level of activity and patient choice. Due to the limited life expectancy of these patients, bioprosthetic valves should be considered, especially since there is no evidence of early degeneration of tissue valves in this subgroup of patients.
INTRODUCTION
A best evidence topic was constructed according to a structured protocol. This is fully described in the ICVTS [1] . 
THREE-PART QUESTION

CLINICAL SCENARIO
In a multidisciplinary team meeting, a 55-year old patient with end-stage renal disease (ESRD) is referred for a valve replacement. You would usually place a mechanical valve in patients of this age but you wonder, with his regular dialysis, potential for renal transplantation and reduced life expectancy, whether a tissue valve would not be better for him so that he can avoid warfarin. You decide to review the literature on this subject.
SEARCH STRATEGY
Medline 1948 to November 2011 with OVID SP (exp Heart Valve Prosthesis/ OR valve replacement.mp. OR AVR.mp) AND (end stage renal disease.mp. or exp Kidney Failure, Chronic/ OR exp Renal Dialysis/ or haemodialysis.mp).
SEARCH OUTCOME
Two hundred and forty-seven papers were found using the reported search. From these, eight papers were identified, which provided the best evidence to answer the question. These are presented in Table 1 .
RESULTS
Thourani et al. [2] studied 211 operations on dialysis patients. One hundred and forty-three received the bioprosthetic (67.8%) and 68 (32.2%) mechanical valves. There was no statistically significant difference in major adverse cardiac adverse factors or survival between the bioprosthetic and mechanical valves.
Herzog et al. [3] studied 5858 dialysis patients needing a valve replacement. The criterion for the inclusion of this study was patients who had undergone dialysis for at least 30 days prior to Hospital mortality similar between the two groups (Group 1: 23%, Group 2: 18%). Mortality of patients during the follow-up period for patients who were on dialysis (39%) compared to not being on dialysis (37%) was not significantly higher. 5-year survival rate for biological valve replacement was 51 ± 10.7 while mechanical valve replacement was 55 ± 8.4
Both mortality and morbidity are high in patients with RF whether they are dialysis-dependent or not and the type of prosthesis did not impact survival valvular surgery. However patients who received concomitant CABG were at increased risk of death by 8%. Tissue valves were used in 881 patients. There was no significant difference in survival related to the type of prosthetic valve implanted. The use of tissue valves was not predictive of death relative risk (RR 0.98; 95% confidence interval (CI) 0.90-1.07). They concluded that there is no significant difference in the survival of dialysis patients after a tissue or mechanical valve replacement. However, the study found that older age (≥75 years), diabetic end-stage renal failure (ESRD), liver disease and double valve replacement to be predictors of death.
Brinkman et al. [4] studied 72 patients. Out of 34 patients with mechanical valves, 17 had significant bleeding or stroke (50%). Only 1 in 12 patients (8.3%) who had bioprosthetic valve replacement had the same outcome (P = 0.016, odds ratio 6.02). Overall early and late survival between the two groups did not differ significantly. They concluded that bioprosthetic valves should be chosen due to the 6-fold increase in bleeding complication in the mechanical valve replacement group.
Chan et al. [5] studied 69 valve replacements; 47 bioprosthetic and 22 mechanical. Freedom from all valve-related complications was 82.8 ± 8.1% in the bioprosthetic valve group and 76.4 ± 12.7% in the mechanical group (not significant). Five-year survival in the mechanical valve replacement group was 52 ± 12.9%, while it was 21.9 ± 7.1% in the bioprosthesis group. This was significant (P = 0.0299). However, patients with bioprosthetic valves were older, had more past MIs myocardial infarctions and had more concomitant revascularization procedures. They concluded that there was no difference in freedom from complications between mechanical and bioprosthetic valve replacement groups.
Filsoufi et al. [6] studied 155 patients with a valve replacement. They concluded that both mortality and morbidity are high in patients with RF regardless of whether they are dialysisdependent or not, and that the type of prosthesis did not affect the survival.
Tanaka et al. [7] studied 73 dialysis patients with aortic valve replacements (51 mechanical and 22 bioprosthetic). In these patients, the valve-related complication was similar. Six of 51 patients in the mechanical group and one of 22 patients in the bioprosthetic group had bleeding risk. Similarly, there were five thromboembolic events in the mechanical group and one in the bioprosthetic group. The valve-related survival rate in both groups were not significantly different (P = 0.202), but the allcause survival rate in the bioprosthetic group was significantly worse (P < 0.001). The authors concluded that valve selection and surgical strategy must be considered on a case-to-case basis to improve the clinical outcomes.
Boeken et al. [8] analysed retrospective data from 104 patients with ESRD who underwent valve replacements. Forty-two percentage patients had undergone mechanical replacement, while 52% had undergone the bioprosthetic valve replacement. In-hospital mortality between the two groups was not statistically significant. However, the patients with mechanical valve replacements had a significantly higher rate of postoperative cerebrovascular accidents (18.2%) compared with those with biological replacement (8.3%, P < 0.05). The other bleeding complications were also significantly higher (15.9 versus 11.7%, P < 0.05). The authors concluded that biological valves should be the preference as the use of mechanical valves is associated with a significant risk of complications. Chan et al. performed a systematic review and meta-analysis of valve replacement in patients with ESRD on dialysis. Twelve studies, published from 1997 to 2010, were included in this review; of which, nine were used in the meta-analysis. No difference in the survival was observed between the valve types (bioprostheses versus mechanical prostheses; hazard ratio 1.3, 95% CI 1.0-1.9, P = 0.09). However, bioprosthetic valves were associated with a fewer valve-related complications compared with mechanical prostheses (odds ratio 0.4, 95% CI 0.2-0.7, P = 0.002). They concluded that there was no survival difference following valve replacement with either bioprostheses or mechanical prostheses in patients with ESRD on dialysis. Bioprosthetic valve replacement was associated with fewer valve-related complications.
CLINICAL BOTTOM LINE
We conclude that the choice of valve in the patients with ESRD should be determined by age, level of activity and patient choice. There is no sufficient evidence to recommend mechanical or tissue valves. Due to the limited life expectancy of these patients, bioprosthetic valves should be considered especially since there is no evidence of early degeneration of tissue valves in this subgroup of patients.
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